Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.31 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.31 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.30 |
| ▸ | ALB | P02768 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.30 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.30 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18879992 | 0.89 | FGFR1 (0.33) | FGFR1SLC22A6LMNATHRBMTOR | |
| SCHEMBL20724461 | 0.89 | FGFR1 (0.33) | FGFR1SLC22A6LMNATHRBMTOR | |
| SCHEMBL19590385 | 0.81 | FGFR1 (0.35) | FGFR1SLC22A6LMNATHRBMTOR | |
| SCHEMBL19993771 | 0.80 | POLG (0.41) | FGFR1SLC22A6 | |
| SCHEMBL18721295 | 0.80 | FGFR1 (0.33) | FGFR1SLC22A6LMNATHRBMTOR | |
| SCHEMBL19993637 | 0.79 | FGFR1 (0.36) | FGFR1SLC22A6LMNATHRBMTOR | |
| SCHEMBL22009122 | 0.79 | FGFR1 (0.32) | FGFR1SLC22A6 | |
| SCHEMBL22010003 | 0.79 | FGFR1 (0.32) | FGFR1SLC22A6 | |
| SCHEMBL20629113 | 0.78 | FGFR1 (0.33) | FGFR1SLC22A6LMNATHRBMTOR | |
| SCHEMBL19590320 | 0.78 | FGFR1 (0.33) | FGFR1SLC22A6LMNATHRBMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3013340-B9 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20170143751-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143751-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | FGFR1 1766/4885SLC22A6 861/4885LMNA 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.